Media coverage
17Media coverage
Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Plus Company Updates (PCU) Country United States Date 12/4/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Canada NewsWire Country Canada Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Canada NewsWire Country Canada Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet PR Newswire Country United States Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Canada NewsWire Country Canada Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet PR Newswire Country United States Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet PR Newswire Country United States Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Morningstar.com Country United States Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Nasdaq Country United States Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet India Pharma News Country India Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet TickerTech.com Country United States Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Spoke.com Country United States Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Stockwatch Country Canada Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet BioSpace Country United States Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet PharmiWeb Country United Kingdom Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Canadian Life Sciences Database Country Switzerland Date 12/3/18 Persons Ruben Mesa Title Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Media name/outlet Central Charts Country France Date 12/3/18 Persons Ruben Mesa